Oxford University and AstraZeneca have announced a third vaccine for the coronavirus which they claim to be at least 90 percent effective.
AstraZeneca said on Monday that their late-stage trials of the potential vaccine, conducted in the U.K. and Brazil, has not resulted in any hospitalizations or severe cases of the coronavirus.
As the Associated Press reports, two different vaccine tests were conducted to determine its effectiveness:
The trial looked at two different dosing regimens. A half dose of the vaccine followed by a full dose at least one month apart was 90% effective. A second regimen using two full doses one month apart was 62% effective. The combined results showed an average efficacy rate of 70%.
Professor Andrew Pollard, who is the chief investigator for the trial, said the potential vaccine operates somewhat differently than other potential vaccines announced by Pfizer and Moderna and would be more easily disputed to those who need it.
“These findings show that we have an effective vaccine that will save many lives,” he said via the report. “Excitingly, we’ve found that one of our dosing regimens maybe around 90% effective.’’
AstraZeneca CEO Pascal Soriot similarly described the potential vaccine as “highly effective” and said it “will have an immediate impact” on ending the global pandemic.
“This vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency,’’ Soriot said.
The Associated Press adds:
The results come as COVID-19 infection rates are rising in most U.S. states and in many countries amid a resurgence of the virus that is once again prompting governments to shut down businesses and restrict social gatherings around the world. England is still in the middle of a four-week lockdown that has closed all non-essential shops, while in the U.S., the government’s top health agency has recommended that Americans not travel to visit family and friends over the Thanksgiving holiday this week.
— Advertisement —
Now that AstraZeneca has released its interim results, regulators must approve the vaccine before it can be widely distributed.
Britain has ordered 100 million doses of the Oxford vaccine, and the government says several million doses can be produced before the end of the year if it gains approval from the regulator.